China Chemical Pharmaceutical Industry Report, 2013-2016
- June 2014
- 131 pages
- Research In China
China is a big producer of chemical APIs, capable of producing about 1,600 varieties of APIs. China ranks first worldwide in output of several bulk APIs including penicillins, vitamins and antipyretic analgesics, and holds a significant share of the featured APIs like statins, prils, sartans in the world. China produced 2.709 million tons of chemical APIs in 2013.
Although China is the world's leading chemical APIs supply region, the concentration of China chemical APIs industry is rather low due to numerous categories of APIs and limited overall strength of domestic enterprises, which occupy an important place only in single or a few categories of pharmaceuticals market. In addition, under the pressure of both environmental protection and industrial upgrading, many large APIs companies in the country are transforming into drug preparation companies through means such as R&D and acquisitions.
North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. are major suppliers of antibiotic and VC APIs in China, with supply of VS reaching around 20,000 tons each. In 2013, the two companies’ total revenue from APIs and their revenue from drug preparation business reached RMB 5.695 billion and RMB 3.871 billion, respectively.
Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd. are the leading manufacturers of VE products around the globe, with raw materials (vital ingredients for the production of VE are limited raw materials: isophytol and trimethylhydroquinone) for VE being produced by themselves. However, the two companies’ development is constrained due to a weak global demand for VE, of which Zhejiang Medicine reported revenue of RMB 4.915 billion from pharmaceutical business (APIs+ preparation), down 6.3% year on year.
Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. are the key suppliers of featured APIs in China, of which the former specializes in antineoplastic and cardiovascular products, and the latter, which obtains three certificates from EDQM in 2013, is a major global supplier of prils and sartans APIs. In 2013, the two companies’ total revenues from APIs and drug preparation business were RMB 3.226 billion and RMB 2.272 billion, rising by 19.5% and 14.7% from the previous year, respectively.
Zhejiang Xianju Pharmaceutical Co., Ltd. and Tianjin Tianyao Pharmaceuticals Co., Ltd. are the leading suppliers of hormone APIs, of which the former has been aggressively expanding into downstream drug preparation business. In the context of stricter environmental standards and rising costs of raw materials, developing the downstream will undoubtedly ensure competitiveness of the company. In 2013, Xianju Pharmaceutical posted total revenue of RMB 2.233 billion from APIs and preparation business, up 16.2% against the prior year. Also in 2013, the company acquired three EDQM certificates for its APIs.
China Chemical Pharmaceutical Industry Report, 2013-2016 highlights the following:
Development status quo, supply and demand, regional structure and trend of global chemical pharmaceutical industry;
Development status quo, competitive landscape, import and export and forecast of China chemical pharmaceutical industry;
Development status quo, competitive landscape and import and export of China chemical pharmaceutical segments, including vitamins, antibiotics, antipyretic analgesics, antineoplastics and cardiovascular and cerebrovascular;
Operation and prospects of 20 Chinese chemical APIs and preparation companies.
1.1 Definition and Classification
1.2 Industry Chain
2. Development of Global Chemical Pharmaceutical Industry
2.1 Status Quo
2.2 Supply and Demand
2.2.1 Product Mix
2.2.1 Regional Structure
2.3 Major Countries and Regions
2.3.1 North America
2.3.3 Emerging Countries
2.4 Development Trends
2.4.1 Proprietary Drugs in Trouble, Generic Drugs with Great Potential
2.4.2 Emerging Countries Being Growth Engines
3. Development of China Chemical Pharmaceutical Industry
3.1 Status Quo
3.1.1 Overall Conditions
3.1.2 Improvement in Pharmaceutical Innovation Capability
3.1.3 Active Merger and Reorganization of Pharmaceutical Companies
3.2 Operating Capability
3.3 Import and Export
3.3.1 Chemical Preparations
3.3.2 Chemical APIs
3.4 Competitive Landscape
4. China Chemical Pharmaceutical Market Segments
4.1.1 Status Quo
4.1.2 Competitive Landscape
4.1.3 Import and Export
4.2.1 Status Quo
4.2.2 Competitive Landscape
4.2.3 Import and Export
4.3 Antipyretic Analgesics
4.3.1 Status Quo
4.3.2 Competitive Landscape
4.3.3 Import and Export
4.4.1 Status Quo
4.4.2 Competitive Landscape
4.4.3 Import and Export
4.5.1 Status Quo
4.5.2 Competitive Landscape
4.6 Cardiovascular and Cerebrovascular
4.6.1 Status Quo
4.6.2 Competitive Landscape
5. Key Chinese Chemical APIs Manufacturers
5.1 Northeast Pharmaceutical Group Co., Ltd.
5.1.3 Revenue Structure
5.2 North China Pharmaceutical Co., Ltd.
5.2.3 Revenue Structure
5.3 Zhejiang Medicine Co., Ltd.
5.3.3 Revenue Structure
5.3.4 Investment and R&D
5.4 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.4.3 Revenue Structure
5.5 Zhejiang NHU Co., Ltd.
5.5.3 Revenue Structure
5.6 Shandong Xinhua Pharmaceutical Company Limited
5.6.3 Revenue Structure
5.7 Shenzhen Hepalink Pharmaceutical Co., Ltd.
5.7.2 Revenue Structure
5.8 Zhejiang Xianju Pharmaceutical Co., Ltd.
5.8.3 Revenue Structure
5.9 Zhejiang Huahai Pharmaceutical Co., Ltd.
5.9.3 Revenue Structure
5.10 Tianjin Tianyao Pharmaceuticals Co., Ltd.
5.10.3 Revenue Structure
5.10.3 Investment and R&D
6. Key Chinese Chemical Preparation Manufacturers
6.1 China Resources Double-Crane Pharmaceutical Co., Ltd.
6.1.3 Revenue Structure
6.1.4 Investment and R&D
6.2 Jiangsu Hengrui Medicine Co., Ltd.
6.2.3 Revenue Structure
6.2.4 R&D and Investment
6.3 Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
6.3.3 Revenue Structure
6.3.4 R&D and Investment
6.4 Xizang Haisco Pharmaceutical Group Co., Ltd.
6.4.3 Revenue Structure
6.4.4 Investment and R&D
6.5 Livzon Pharmaceutical Group Inc.
6.5.3 Revenue Structure
6.6 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
6.6.3 Revenue Structure
6.6.4 R&D and Investment
6.7 Jiangsu Nhwa Pharmaceutical Co., Ltd.
6.7.3 Revenue Structure
6.8 Hainan Haiyao Co., Ltd.
6.8.3 Revenue Structure
6.9 Huaren Pharmaceutical Co., Ltd.
6.9.3 Revenue Structure
6.9.4 Investment and R&D
6.10 Humanwell Healthcare (Group) Co., Ltd.
6.10.3 Revenue Structure
6.10.4 Investment and R&D
7. Conclusion and Forecast
7.1.1 Market Size Forecast
7.1.2 Profit Forecast
Northeast Pharmaceutical Group Co., Ltd.
North China Pharmaceutical Co., Ltd.
Zhejiang Medicine Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang NHU Co., Ltd.
Shandong Xinhua Pharmaceutical Company Limited
Shenzhen Hepalink Pharmaceutical Co., Ltd.
Zhejiang Xianju Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tianjin Tianyao Pharmaceuticals Co., Ltd.
China Resources Double-Crane Pharmaceutical Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
Xizang Haisco Pharmaceutical Group Co., Ltd.
Livzon Pharmaceutical Group Inc.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Hainan Haiyao Co., Ltd.
Huaren Pharmaceutical Co., Ltd.
Humanwell Healthcare (Group) Co., Ltd.